Extended Data Fig. 2: Impacts of a Lassa vaccine effective against infection and disease.
From: Health and economic impacts of Lassa vaccination campaigns in West Africa
(A) The mean cumulative number of LASV infections averted due to vaccination across the 15 countries included in the model, comparing vaccine efficacy against infection and disease of 70% (blue) versus 90% (red) across the six considered vaccination scenarios (panels). 95% uncertainty intervals are indicated by shading. (B) The mean cumulative number of infections averted over ten years under each vaccination scenario in the four countries classified as high-endemic (Guinea, Liberia, Nigeria and Sierra Leone). 95% uncertainty intervals are indicated by error bars (n = 9,900). (C) The mean cumulative incidence of infections averted over ten years per 100,000 population under each vaccination scenario in the same four countries. 95% uncertainty intervals are indicated by error bars (n = 9,900). (D) The mean daily number of infections averted by a vaccine with 70% efficacy against infection and disease over the first three years of vaccine rollout, in three distinct districts under four selected vaccination scenarios. 95% uncertainty intervals are indicated by shading.
